unit state go sg websit
ultim healthcar proxi cost
upsid tp
lead posit three pillar pharma med-tech consum
give healthcar proxi statu low volatil see bull/bear
approach expect
lower growth absenc
acquisit due patent expiri stronger competit follow
out-performance vs pharma last three year believ
fulli valu current premium vs pharma broadli line
averag
share outperform us pharma sector last month
under-perform last three month consid key
nc chang
healthcar proxi given size three pillar pharma med-tech consum
success
histor
remicade/simponi stelara still sale recent success blood
cancer darzalex imbruvica grow dynam success
collabor bayer cardiolog xarelto us compani one
top five pharma player also expos gener risk neurolog cancer
cardio lt biosimilar
remicad
overal exposur
correspond group sale pharma view mid-single-
digit growth target becom difficult achiev view patent expiri
difficult competit landscap despit ramp-up new product despit
favour impact us tax reform industri lower tax rate
battl acquir asset strengthen portfolio support growth becom
fulli valu show premium vs pharma sector price-to-earnings
justifi good visibl offer three busi given patent
expiri stronger competit histor franchis despit new product
launch diversif life-cycl manag expect earn grow
organ period estim slightli
consensu mainli stellara simponi bull/bear approach show
balanc profil rather modest volatil ebit justifi
jnj healthcar proxi statu believ alreadi reflect current
valuat see limit catalyst year although new result xarelto
help heart failur market expect alreadi high super-blockbust
cut tp vs reflect low sector multipl long-term margin
societ general sg seek busi compani cover research report result investor awar
sg may conflict interest could affect object report investor consid report singl factor
make invest decis pleas appendix end report analyst certif
largest compani univers term sale explain
diversifi profil given exposur med-tech mainli cardiovascular surgeri
orthopaed consum over-the-counter also oral care beauti care three divis
see med-tech account third total group sale almost twice
size consum see term oper profit contribut pharma still
account half busi consum rather small less volatil
pharma due lower patent expiri risk
pharma well-establish presenc immuno-inflamm pioneer
rheumatoid arthriti psoriasi anti-tnf respect remicade/simponi
stelara continu develop follow-up compound tremfya/guselkumab psoriasi
approv recent expect franchis gradual erod biosimilar new
entrant emerg especi follow failur sirukumab rheumatoid arthriti
cardiolog us partner bayer new oral anticoagul noac
recent benefit new clinic trial result expand elig popul see
specif section bayer nevertheless drug set lose patent august
oncolog benefit imbruvica continu success blood cancer
tumour neurosci expect erod gradual due loss patent
exclus sever product
overal forecast low single-digit sale growth pharma busi midterm
actelion acquisit imbruvica help off-set gradual
eros tail product howev longer term slow portfolio rejuven like
lead slowdown absenc acquisit patent expiri xarelto
neurosci product weigh growth see
shown chart main headwind genericis product
remicad antitnf immuno-inflamm prezista hiv velcad zytiga
oncolog tail portfolio combin product account pharma sale
total group sale meanwhil recent launch product imbruvica darzalex
off-set declin contribut consum med-tech divis
help group deliv low single-digit growth compound-annual-growth-rate
interestingli non-pharma divis combin account sale
growth domin med-tech
volatil pharma sale growth explain anticip patent expiri
notabl xarelto us new product launch integr actelion
chang scope med-tech divis explain growth underli
level closer low mid-single-digit rang
ebita margin group divis
sale growth divis group
estim broadli line consensu slightli conserv simponi
stelara vs consensu see competit new
entrant weigh perform product although also expand
market
target price averag sum-of-the-part valuat dcf target price
stock would trade premium pharma sector price-to-earnings adjust
tp reflect lower sector multipl follow recent market downturn revis
lower long-term estim follow updat immune-inflamm model
stronger eros stelara due competit lead lower margin
part
pharma sector premium pharma med-tech
consum
appli follow assumpt sotp
pharma valu premium pharma peer
med-tech valu premium larg pharma peer group given better visibl
high margin
consum valu premium larg pharma peer given good visibl despit
sum part
multipl premium/discount
multipl premium/discount
multipl premium/discount
shown sotp breakdown half jnj valu come pharma
med-tech come fairli distant second lower absolut contribut high margin
sotp breakdown divis averag /share
chart show jnj ep growth profil attract compound-annual-growth-rate
vs peer also group face patent expiri slightli
off-set pipelin non-pharma divis
bull/bear approach show balanc profil ebita
limit risk pipelin rel low expect hand
uncertainti much higher major product darzalex xarelto stellara
lesser extent med-tech
bull/bear approach impact sale
bull/bear approach impact ebita
bull/bear approach impact sale categori
bull/bear approach impact ebita categori
jnj forward price-to-earnings show premium vs us pharma peer broadli
line ten-year averag far record high reach rest
industri hit patent cliff uncertainti tp would trade premium
pharma sector believ deserv given healthcar proxi statu
newsflow xarelto back forefront market expect alreadi high
new xarelto indic follow compass result announc last year new trial
result heart failur command hf help off-set loss patent
expiri stronger competit variou area although market expect alreadi
high super-blockbust
potenti new line extens stellara uc could help establish franchis
tremfya psoriasi
coronari arteri diseas cad peripher arteri diseas pad
potenti approv base compass result
non-pharma busi lead posit sever med-tech consum
lead med-tech compani strong posit
orthopaed number one depuy/synth joint reconstruct trauma spine
cardiovascular surgeri cordi
vision care contact lens compet novartis/alcon strengthen amo
divis abbott gave access cataract surgeri market
consum side boast broad portfolio still rank number four over-the-counter
despit recent move sanofi boehring ingelheim
forecast low single-digit growth busi visibl remain satisfactori
less volatil pharma
bull/bear scenario potenti impact ebit
impact
growth declin
stronger pressur biosimilar
growth
declin due new entrant
declin due new entrant
biosimilar tnf class
growth due eliqui competit
lower warfarin switch
declin due competit
limit indic refractori
competit
growth higher margin
growth lower margin
approv
product sold
equival
total liabil equiti
chang work capit
flow oper activ
flow invest activ
net chang debt
proce issue/buyback share
flow financ activ
effect foreign exchang
net chang cash/cash equival
begin year
end year
share basic year end/outstand
share price average hist yr current
new york mellon corp
valu minor
valu financi invest
depreci amortis
chang work capit
flow oper activ
flow invest activ
flow financ activ
net chang cash result cf
intang
report complet cet
merck co inc us buy
follow name research analyst herebi certifi certifi view express research report accur reflect
person view subject secur issuer ii part compens
relat directli indirectli specif recommend view express report florent cesped
analyst author research employ sg affili locat includ limit pari london new york
hong kong tokyo bangalor frankfurt madrid milan seoul warsaw
deriv target price sotp averag ev/ebita larg pharma multipl premium consum
med-tech pharma dcf lt growth lt ebita margin wacc
downsid risk non-pharma activ could becom volatil price pressur neg low single-digit impact group ebita
xarelto cardio could face pressur bms/pfe eliqui neg low single-digit impact faster eros remicad due
upsid risk remicad eros could prove slower expect posit mid single-digit impact ebita
sg equiti research rate month period
buy absolut total sharehold return forecast
month period
equiti rate dispers relationship
hold absolut total sharehold return forecast
month period
sell absolut total sharehold return forecast
plu forecast cash dividend incom includ incom
special dividend paid month period rate
determin rang describ time
initi coverag chang rate subject limit
manag discret time rate may fall outsid
rang market price movement and/or
short term volatil trade pattern interim deviat
specifi rang permit becom subject
review research manag
sector weight definit month period
sector weight assign sg equiti research
strategist distinct separ sg equiti research
analyst rate base relev
overweight sector expect outperform relev broad
market benchmark next month
neutral sector expect perform in-lin relev
broad market benchmark next month
underweight sector expect under-perform relev
broad market benchmark next month
prefer least prefer stock select
cover analyst base individu analyst coverag
univers sg equiti research strategist
price inform includ report market close unless otherwis state
disclaim sourc inform exclus properti morgan stanley capit intern inc without
prior written permiss inform intellectu properti may reproduc redissemin
use creat financi product includ indic inform provid basi user assum entir
risk use made inform affili third parti involv relat comput compil
inform herebi expressli disclaim warranti origin accuraci complet merchant fit particular
purpos respect inform without limit forego event shall affili
third parti involv relat comput compil inform liabil damag kind morgan
stanley capit intern index servic mark affili similar languag may
provid approv advanc
sg act co-manag novarti financ sa bond issu senior
sg act co-manag novarti financ bond
